TOKYO – Takeda Pharmaceutical Co. Ltd. fell far short of its financial year guidance and forecasts for the next year disappointed analysts. The dismal figures were attributed to higher-than-expected expenditures, and the company released details of a plan to rein in costs through 2017 to improve margins.
“At last year’s earnings meeting, I told you I see light at the end of the tunnel. One year later,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?